Clinical Trials
28 trialsPSMACare
Novartis
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
PREDICT
Alliance for Clinical Trials in Oncology
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
Case Comprehensive Cancer Center
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
M.D. Anderson Cancer Center
PSMAndARPI
Novartis
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Canadian Cancer Trials Group
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Novartis
Bullseye
Radboud University Medical Center
LASER
Dana-Farber Cancer Institute
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
ReaLuP
Hospices Civils de Lyon
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
VA Office of Research and Development
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
CATCH-177
Case Comprehensive Cancer Center
UpFrontPSMA
Peter MacCallum Cancer Centre, Australia
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Excel Diagnostics and Nuclear Oncology Center
PSMA-ADJUVO
Maria Sklodowska-Curie National Research Institute of Oncology
RENALUT
European Organisation for Research and Treatment of Cancer - EORTC
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
RESIST-PC
Endocyte